The AbbVie Q2 2026 Results demonstrate the company’s successful transition beyond its blockbuster drug Humira. Strong growth from Skyrizi and Rinvoq helped AbbVie deliver better-than-expected financial performance despite increasing biosimilar competition. The company’s revenue, earnings, and expanding immunology portfolio highlight its long-term growth strategy.
Quick Summary
AbbVie reported strong Q2 2026 results, posting USD 16.99 billion in revenue, up 10.2% year over year. Skyrizi and Rinvoq each grew more than 24%, offsetting Humira’s continued decline due to biosimilars. Although AbbVie slightly reduced its full-year earnings guidance following its planned Apogee Therapeutics acquisition, analysts remain optimistic about the company’s long-term growth.
Overview
AbbVie has announced impressive financial results for the second quarter of 2026, outperforming market expectations through continued demand for its leading immunology medicines.
While Humira continues to lose market share because of biosimilar competition, newer therapies including Skyrizi and Rinvoq have successfully become the company’s primary growth drivers.
AbbVie Q2 2026 Financial Highlights
| Metric | Q2 2026 |
|---|---|
| Revenue | USD 16.99 Billion |
| Revenue Growth | 10.2% YoY |
| Adjusted EPS | USD 3.65 |
| GAAP EPS | USD 2.03 |
| Analyst Expectation | Exceeded |
| Full-Year EPS Guidance | USD 13.87–14.07 |
Skyrizi Continues Strong Growth
AbbVie’s blockbuster immunology medicine Skyrizi remained the company’s highest-performing product.
Performance
- Revenue: USD 5.51 Billion
- Growth: 24.4% YoY
Skyrizi continues expanding across several autoimmune diseases, including:
- Plaque Psoriasis
- Psoriatic Arthritis
- Crohn’s Disease
- Ulcerative Colitis
Rinvoq Delivers Another Excellent Quarter
Rinvoq also maintained strong momentum.
| Metric | Value |
|---|---|
| Revenue | USD 2.53 Billion |
| Growth | 24.5% YoY |
The medicine continues gaining approvals for multiple inflammatory diseases, helping AbbVie strengthen its immunology portfolio.
Humira Sales Continue to Decline
Humira remained under pressure due to increasing biosimilar competition.
Key Points
- Sales declined nearly 36%
- Multiple biosimilars entered global markets
- Skyrizi and Rinvoq successfully replaced much of the lost revenue
AbbVie’s diversification strategy appears to be working effectively.
Immunology Business Remains the Largest Growth Driver
AbbVie’s immunology portfolio generated:
- USD 8.79 Billion Revenue
- More than 15% YoY Growth
The company’s leadership in autoimmune disease treatment continues to strengthen.
Neuroscience Portfolio Shows Strong Growth
AbbVie’s neuroscience business also delivered impressive performance.
Major growth products included:
- Vraylar
- Botox Therapeutic
- Ubrelvy
- Qulipta
- Vyalev
Overall neuroscience revenue increased by more than 20%.
Full-Year 2026 Guidance
Despite strong quarterly performance, AbbVie slightly lowered its adjusted earnings guidance.
| Guidance | Value |
|---|---|
| Previous Guidance | Higher |
| Updated Guidance | USD 13.87–14.07 |
The revision reflects the expected financial impact of the planned USD 10.9 billion acquisition of Apogee Therapeutics.
Why Is AbbVie Acquiring Apogee Therapeutics?
The acquisition aims to strengthen AbbVie’s future immunology pipeline.
Expected benefits include:
- Advanced eczema treatments
- Asthma therapies
- New inflammatory disease medicines
- Stronger long-term product pipeline
Although the acquisition may reduce short-term earnings, it is expected to support sustainable future growth.
CEO Statement
AbbVie CEO Robert A. Michael stated that the company continues building momentum through:
- Strong commercial execution
- Regulatory progress
- Innovative medicine launches
- Strategic investments
- Expansion of its research pipeline
Analyst View
Market analysts believe AbbVie has successfully transitioned beyond Humira.
Positive observations include:
- Skyrizi continues outperforming expectations.
- Rinvoq remains one of the fastest-growing immunology medicines.
- Humira’s declining sales are increasingly offset by newer products.
- The Apogee acquisition could further strengthen AbbVie’s future growth.
Investors will continue monitoring the integration of Apogee Therapeutics and future earnings performance.
Key Takeaways
| Highlights | Details |
|---|---|
| Revenue | USD 16.99 Billion |
| Revenue Growth | 10.2% |
| Best Performing Drug | Skyrizi |
| Fastest Growing Product | Rinvoq |
| Biggest Challenge | Humira Biosimilars |
| Future Focus | Apogee Therapeutics Acquisition |
Frequently Asked Questions (FAQs)
1. What was AbbVie’s Q2 2026 revenue?
AbbVie reported USD 16.99 billion in revenue during Q2 2026.
2. Which AbbVie products drove revenue growth?
Skyrizi and Rinvoq were the primary drivers of revenue growth.
3. Why are Humira sales declining?
Humira sales are declining because multiple lower-cost biosimilars have entered the market.
4. How much did Skyrizi generate in Q2 2026?
Skyrizi generated USD 5.51 billion in quarterly revenue.
5. What was Rinvoq’s revenue?
Rinvoq reported USD 2.53 billion in Q2 2026.
6. Why did AbbVie lower its earnings guidance?
The company lowered its guidance due to the expected financial impact of its planned acquisition of Apogee Therapeutics.
7. What is AbbVie’s biggest business segment?
Immunology remains AbbVie’s largest and fastest-growing business segment.
8. Is AbbVie still growing despite Humira’s decline?
Yes. Strong sales of Skyrizi and Rinvoq have more than compensated for much of Humira’s revenue decline.
Recommended Products
